Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
PaperCitations, authors & open-access status
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 530 citations, 2017 year and closed oa status.
530
Citations
2017
Year
closed
OA Status